Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
Lymphoma
About this trial
This is an interventional diagnostic trial for Lymphoma focused on measuring contiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, stage I adult diffuse large cell lymphoma, stage III adult diffuse large cell lymphoma, stage IV adult diffuse large cell lymphoma, contiguous stage II grade 3 follicular lymphoma, noncontiguous stage II grade 3 follicular lymphoma, stage I grade 3 follicular lymphoma, stage III grade 3 follicular lymphoma, stage IV grade 3 follicular lymphoma, anaplastic large cell lymphoma, stage I adult T-cell leukemia/lymphoma, stage II adult T-cell leukemia/lymphoma, stage III adult T-cell leukemia/lymphoma, stage IV adult T-cell leukemia/lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following subtypes: Diffuse large B-cell lymphoma Mediastinal (thymic) B-cell lymphoma Grade 3 follicular lymphoma Anaplastic large cell lymphoma Peripheral T-cell lymphoma Must have adequate staging of disease by the following techniques: CT scan or MRI of affected sites Bone marrow biopsy (in cases where results influence the duration of chemotherapy only) Lumbar puncture (if clinically indicated) Stage I-IV disease Any International Prognostic Index risk category Radiographically measurable disease None of the following aggressive non-Hodgkin's subtypes are allowed: Mantle cell lymphoma Lymphoblastic lymphoma Burkitt's lymphoma Mycosis fungoides/Sezary's syndrome HTLV-1-associated T-cell leukemia/lymphoma Primary CNS lymphoma HIV-associated lymphoma Transformed lymphomas No prior diagnosis of another hematologic malignancy No known progressive disease during prior first-line chemotherapy No active CNS involvement by lymphoma, except CNS involvement at diagnosis that is previously treated and in remission PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-4 (0-2 for peripheral blood stem cell [PBSC] or bone marrow transplantation [BMT] patients) Life expectancy Not specified Hematopoietic Absolute neutrophil count > 1,000/mm^3* Platelet count ≥ 75,000/mm^3 NOTE: *PBSC or BMT patients only Hepatic Bilirubin ≤ 2.0 mg/dL unless due to Gilbert's disease or lymphoma* No known significant hepatic dysfunction that is not expected to improve and would preclude PBSC or BMT NOTE: *PBSC or BMT patients only Renal Creatinine ≤ 2.0 mg/dL* No known significant renal dysfunction that is not expected to improve and would preclude PBSC or BMT NOTE: *PBSC or BMT patients only Cardiovascular Ejection fraction ≥ 45% by echocardiogram or MUGA* No known significant cardiac dysfunction that is not expected to improve and would preclude PBSC or BMT NOTE: *PBSC or BMT patients only; a cardiology consult and evaluation may override ejection fraction criterion Pulmonary FEV_1 and FVC ≥ 50% of predicted for patients who have not received thoracic or mantle radiotherapy (75% of predicted for patients who have received thoracic or mantle radiotherapy)* No known significant pulmonary dysfunction that is not expected to improve and would preclude PBSC or BMT NOTE: *PBSC or BMT patients only Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 3 years except carcinoma in situ of the cervix or nonmelanoma skin cancer No known HIV positivity OR HIV negative (for PBSC or BMT patients only) No serious illness that would preclude study participation No contraindication to autologous BMT PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy See Disease Characteristics No more than 3 prior courses of chemotherapy for lymphoma Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified
Sites / Locations
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins